Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASALTS:0OCD 99 ROC (Joel Greenblatt) % is 95.34% as of Mar. 2026, which is 42% above its 10-year median of 67.20. GuruFocus rates LTS:0OCD with a GF Score™ of 99/100 and a GF Value™ of kr257.36 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 838 Medical Devices & Instruments companies, Medistim ASA ranks better than 96.3% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Medistim ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 95.34%.
The historical rank and industry rank for Medistim ASA's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0OCD'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.23 Med: 67.2 Max: 98
Current: 91.55
During the past 13 years, Medistim ASA's highest ROC (Joel Greenblatt) % was 98.00%. The lowest was 51.23%. And the median was 67.20%.
LTS:0OCD's ROC (Joel Greenblatt) % is ranked better than 96.3% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs LTS:0OCD: 91.55
Medistim ASA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 8.90% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Medistim ASA ROC (Joel Greenblatt) % Related Terms
Medistim ASA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Medistim ASA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0OCD vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Medistim ASA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 95.34% mean?
Medistim ASA (LTS:0OCD) has a ROC (Joel Greenblatt) % of 95.34% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medistim ASA and its competitors. This is 42% above median its historical median of 67.20. Over the past decade, Medistim ASA's ROC (Joel Greenblatt) % has ranged from 51.23 to 98.00. According to the industry distribution chart, Medistim ASA ranks #31 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 3.7%.
Is Medistim ASA's ROC (Joel Greenblatt) % too high?
Medistim ASA's current ROC (Joel Greenblatt) % of 95.34% is 42% above median its 10-year median of 67.20. Over the past 10 years, this metric has ranged from a low of 51.23 to a high of 98.00. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Medistim ASA's value of 95.34% is 2200.1% above this industry median. Based on the distribution chart, Medistim ASA ranks #31 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #31 out of 838 companies for ROC (Joel Greenblatt) %. This places Medistim ASA in the top 4% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Medistim ASA's value of 95.34% is 2200.1% above this benchmark. Historically, Medistim ASA's own ROC (Joel Greenblatt) % has ranged from 51.23 to 98.00 over the past decade. While the company's 10-year median is 67.20 vs. the industry median of 4.15, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current ROC (Joel Greenblatt) % of 95.34% is 2200.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current ROC (Joel Greenblatt) % is 95.34%, which is 42% above median its own 10-year median of 67.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Modestly Undervalued. The stock's GF Value™ is kr257.36, compared to a current price of kr231.00 — trading 10.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 95.34%, which is 42% above median its 10-year median of 67.20 and 2200.1% above the Medical Devices & Instruments industry median of 4.15. Medistim ASA's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current ROC (Joel Greenblatt) % is 95.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (LTS:0OCD) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of kr231.00 is trading 10.2% below its estimated GF Value™ of kr257.36.
GuruFocus considers Medistim ASA to be Modestly Undervalued.
Key valuation signals for LTS:0OCD:
ROC (Joel Greenblatt) %: 95.34% (42% above median its 10-year median of 67.20)
GF Value™: kr257.36 vs. price of kr231.00 (10.2% below fair value)
Industry Position: 2200.1% above the Medical Devices & Instruments median (#31 of 838)
No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
99GF Score
Get the complete analysis for LTS:0OCD
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0OCD has been successfully added to your 
